Join Now

Committee Blog: Why Insurance Companies Should Cover Medical Cannabis Now

by Carol Welch & Jim Gerencser
NCIA’s Risk Management & Insurance Committee

Cannabis was legalized for medical use in California in 1996. Since then, 47 states, the District of Columbia, and three territories (Puerto Rico, Guam, and CNMI) have legalized some form of cannabis, leaving only three states with no legal use. Thirty-six states have an effective medical use law in place. The main reason insurance companies haven’t had to consider providing coverage for patients is because federally cannabis is still listed as a Schedule 1 drug. Even though the likelihood of cannabis being legalized nationally seems bound to happen within the next few years, insurance companies should start planning to incorporate new cannabis policies into their plans now.

Here are five great reasons to cover medical cannabis:

SAVES MONEY

Science has proven that cannabis helps over 60% of epilepsy patients decrease the frequency and severity of seizures. Cannabis products should cost less than traditional epilepsy medications, especially when taking into account the added prescriptions often needed to combat the side effects of currently available prescription drugs.

Compared to the traditional cost of cancer treatment, patients opting to skip conventional treatments for cannabis could save their insurance companies thousands in initial cancer treatment, and potentially will have less recurrence and costly maintenance prescriptions.

Insurance companies are paying billions in healthcare costs to include doctor visits, lab tests, hospital admissions and prescriptions for conditions that cannabis has shown to improve dramatically. Chronic pain, depression and PTSD are all treatable with cannabis, and cannabis is much less dangerous than the opioids that are commonly prescribed in chronic pain cases.

SAVES LIVES

There are no known deaths reported from cannabis consumption alone. According to the CDC, there were 70,630 deaths due to drug overdose in 2019. In addition, there are estimates of over 1.5 million hospitalizations per year from adverse drug reactions that don’t cause death but are still costly to many people. Insurance companies can avoid some of the negative PR, potential litigation and upset related to deaths caused by pharmaceuticals, while providing patients with a solution that works for many conditions.

Research is increasingly showing that certain strains and compounds within the cannabis plant can have a significant positive effect on several conditions. For instance, breast cancer responds very well to FECO (full extract cannabis oil), with lab tests showing how cannabis causes cancer cell death. More study is still needed, and that is currently being conducted in Israel where there are fewer legal barriers to research.

REDUCES MEDICARE SPENDING

Data from all prescriptions filled by Medicare Part D enrollees from 2010-2013 showed a significant decrease in prescriptions being filled for symptoms for which cannabis could serve as an alternative treatment. Overall reduction in Medicare spending in states that implemented medical marijuana laws were estimated to be $165.2 million per year (2013).  This one difference alone could mean billions in savings for insurance companies in the coming years.

IMPROVES SATISFACTION RATINGS

Let’s face it, insurance is a competitive business. Several large health insurers cover most of the country and will likely be the last to jump on board to cover medical cannabis. But for the smaller, regional or state-specific insurers out there, adding cannabis to the coverage lineup in legal states can provide a competitive advantage with employers and group plans.

Medical cannabis is listed as an eligible expense in many Canadian companies’ HSAs and is listed as an eligible medical expense by the Canada Revenue Agency. Since our northern neighbors are starting to cover it, hopefully that will encourage U.S. insurers to do the same.

IT’S THE RIGHT THING TO DO

Cancer is the #2 leading cause of death in the United States and can cost several thousand dollars for treatment. Using cannabis as a complementary treatment to traditional cancer therapies could decrease the cost of treating cancer to the patient, to the insurance companies and in the end to all of the people across the United States that contribute to Medicare and Medicaid.    

If you would like to take action, contact your legislators to push for the federal legalization of cannabis or sign this petition calling on all U.S. insurers to step up and cover medical marijuana for their patients. Here’s a link to the Care2 petition: Health Insurance Companies Should Cover Medical Marijuana Now.

 

 

 

 

Webinar: Policy Council Conversations: Just Say No – Keep the DEA out of Cannabis Research

NCIA’s #IndustryEssentials educational webinar series is our new digital platform featuring a variety of programs to provide you timely, engaging, and essential education when & where you need it most!

The Policy Council Conversations series features insights & invaluable content directly from members of NCIA’s Policy Council, the preeminent “Think Tank” for the cannabis industry.

The Drug Enforcement Administration recently issued a notice of proposed rulemaking on cannabis research. If adopted, this rule would fundamentally change how cannabis research is conducted. NCIA recently submitted public comments, rejecting the DEA’s power grab and strongly suggesting that a public health agency (i.e. Health and Human Services, National Institutes of Health, etc.) lead on cannabis research. Simultaneously, lawyers at Yetter Coleman filed a Freedom of Information Act lawsuit against DOJ, demanding the release of an OLC memo relied upon by DEA in their rulemaking. That successful suit was brought on behalf of Scottsdale Research Institute.

This panel will discuss the critical importance of cannabis research, the DEA rulemaking and NCIA’s numerous objections, and the lawsuit against DEA and the resulting disclosure of the DOJ policy memo.

Register now to join us on Wednesday, June 3 at 12:00 PM MT.

REGISTER NOW

Panelists:

Jodi Avergun
Chair, White Collar and Criminal Defense and Investigations Group
Cadwalader, Wickersham & Taft LLP
&
Former Chief of Staff
Drug Enforcement Administration (DEA)

Andrew Kline
Director of Public Policy
National Cannabis Industry Association

Sue Sisley, MD
Principal Investigator
Scottsdale Research Institute

Matt Zorn
Associate
Yetter Coleman

Shane Pennington
Associate
Yetter Coleman

Is Medical Marijuana the Answer to the Prescription Painkiller Epidemic?

A new study suggests that access to medical marijuana could dramatically reduce the number of prescription painkiller deaths in the United States.

tablets-193666_640Research published this week in JAMA Internal Medicine reports that states that have legalized medical marijuana saw 25% fewer deaths from prescription painkiller overdoses between 1999 and 2010 than states where cannabis was illegal.

As the Washington Post reports, “That meant 1,729 fewer deaths than expected in 2010 alone, and states saw their overdose rates generally improve each year after their medical marijuana laws were passed, researchers found.”

The CDC reports that 100 people die from drug overdoses every day in the U.S., and prescription painkillers account for nearly three-quarters of that number. Drug overdose death rates have more than tripled since 1990. Consumer Reports recently published an in-depth report on the dangers posed by Americans’ overuse of painkillers.

The JAMA Internal Medicine research was not designed to determine if access to medical marijuana is the primary cause of lower prescription painkiller death rates. But the data suggests there would be significant value in more research on medical cannabis as a replacement or supplement for standard prescription painkiller regimens.

Previous research has shown that patients who use marijuana in addition to prescribed opiate painkillers can manage their pain with significantly lower doses of the opiates than patients using prescription drugs alone.

Have you or any of your patients made the transition from opiates to medical marijuana for pain management? Share your story in the comments section below.

 

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.